ArticlePloS one2026
Computational modeling for rational design of novel phenoxy tacrine derivatives targeting Alzheimer's disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- IntegratedFrontiers in chemistry · 2026Article
- Multiscale mechanistic modeling for the rational design of novel dual-target candidates against acetylcholinesterase and NADPH oxidase: an advanced computational study.Frontiers in chemistry · 2026Article
- Thymol and Limonene as Potent Antimicrobials: Bridging In Vitro Efficacy and Molecular Docking Insights.International journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's is the leading factor behind dementia, producing steady impairments in memory, cognitive reasoning, behavioral, and social interactions. This scientific study investigates thirty-two phenoxy tacrine (PhO-THA) derivatives through an integrated computational modeling to identify potential therapeutic candidates. 3D-QSAR models were developed using comparative molecular similarity indices analysis and comparative molecular field analysis, which were subjected to rigorous internal and external validation to establish a robust quantitative relationship between molecular interaction fields and cytotoxic activities. Based on these validated structural insights, fourteen new compounds (D1-D14) were designed. Comprehensive molecular docking and molecular dynamics (MD) simulations, coupled with ADME-Tox profiling, were used to evaluate their pharmacological potential. Our results highlight four specific compounds (D9-D12) that exhibit favorable pharmacokinetic properties and a high safety profile, making them promising candidates for future drug development. D9 was selected for MD simulations due to its lower cytotoxic activity (pIC50 of 3.50), which is comparable to the reference THA drug (pIC50 of 3.52). The results demonstrated exceptional thermodynamic stability for D9 upon complexation with the NMDA receptor (PDB ID: 5EWJ) over a 100 ns simulation time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.